EMA Authorised: Tremfya — Janssen-Cilag International NV

View source ↗

Summary

EU authorises Tremfya to treat psoriasis, Crohn's disease, and ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Ulcerative Colitis

Drugs mentioned

• TREMFYA (guselkumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Crohn Disease;Colitis, Ulcerative. MAH: Janssen-Cilag International NV. Decision date: 23/03/2026